LB PHARMACEUTICALS INC 8-K

What Happened
LB Pharmaceuticals Inc. announced the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026, where a quorum was present. Stockholders elected three Class I directors — Robert A. Lenz, M.D., Ph.D.; Rebecca Luse; and Ran Nussbaum — each to a three-year term expiring at the 2029 Annual Meeting. Stockholders also ratified the appointment of BDO USA, P.C. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Director election vote totals:
  • Robert A. Lenz, M.D., Ph.D.: For 20,059,577; Withheld 8,004; Broker non-votes 3,216,636.
  • Rebecca Luse: For 18,530,680; Withheld 1,536,901; Broker non-votes 3,216,636.
  • Ran Nussbaum: For 18,748,511; Withheld 1,319,070; Broker non-votes 3,216,636.
• Auditor ratification vote: For 23,275,974; Against 5,490; Abstain 2,753; Broker non-votes — none.
• The proposals were described in the company’s definitive proxy filed with the SEC on April 23, 2026.

Why It Matters
These results confirm shareholder support for the company’s nominated directors and its choice of independent auditor, which affects corporate governance and oversight of financial reporting. The presence of broker non-votes on the director elections indicates some shares held by brokers did not vote on those items; the auditor ratification drew overwhelming shareholder approval. Investors should view this as routine corporate governance activity with no immediate change to operations or financial statements disclosed in the 8-K.